Abstract:A new coronavirus SARS-CoV-2 has caused over 9.2 million infection cases and 475758 deaths worldwide. Due to the rapid dissemination and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2. An in silico approach based on the available virus genome was applied to identify 19 high immunogenic B-cell epitopes and 499 human-leukocyte-antigen (HLA) restricted T-cell epitopes. Thirty multi-epitope peptide vaccines were designed by iNeo Suite, and manufactured by solid-phase synthesis. Docking analysis showed stable hydrogen bonds of epitopes with their corresponding HLA alleles. When four vaccine peptide candidates from the spike protein of SARS-CoV-2 were selected to immunize mice, a significantly larger amount of IgG in serum as well as an increase of CD19+ cells in ILNs was observed in peptide-immunized mice compared to the control mice. The ratio of IFN-γ-secreting lymphocytes in CD4+ or CD8+ cells in the peptides-immunized mice were higher than that in the control mice. There were also a larger number of IFN-γ-secreting T cells in spleen in the peptides-immunized mice. This study screened antigenic B-cell and T-cell epitopes in all encoded proteins of SARS-CoV-2, and further designed multi-epitope based peptide vaccine against viral structural proteins. The obtained vaccine peptides successfully elicited specific humoral and cellular immune responses in mice. Primate experiments and clinical trial are urgently required to validate the efficacy and safety of these vaccine peptides. Importance So far, a new coronavirus SARS-CoV-2 has caused over 9.2 million infection cases and 475758 deaths worldwide. Due to the rapid dissemination and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2. Different from the development approaches for traditional vaccines, the development of our peptide vaccine is faster and simpler. In this study, we performed an in silico approach to identify the antigenic B-cell epitopes and human-leukocyte-antigen (HLA) restricted T-cell epitopes, and designed a panel of multi-epitope peptide vaccines. The resulting SARS-CoV-2 multi-epitope peptide vaccine could elicit specific humoral and cellular immune responses in mice efficiently, displaying its great potential in our fight of COVID-19. ### Competing Interest Statement The authors have declared no competing interest.

Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates.

A Single Dose SARS-CoV-2 Simulating Particle Vaccine Induces Potent Neutralizing Activities

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

Epitope-based peptide vaccine design and target site characterization against novel coronavirus disease caused by SARS-CoV-2

Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2

Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus (SARS-CoV-2)

Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine

A Peptide-Based Subunit Candidate Vaccine Against SARS-CoV-2 Delivered by Biodegradable Mesoporous Silica Nanoparticles Induced High Humoral and Cellular Immunity in Mice.

Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV-2

Preclinical Development of a Novel Epitope-based DNA Vaccine Candidate against SARS-CoV-2 and Evaluation of Immunogenicity in BALB/c Mice

Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

Multi-epitopevaccine design using an immunoinformaticsapproach for 2019 novelcoronavirus in China (SARS-CoV-2)

Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential.

Methods to Identify Immunogenic Peptides in SARS‐CoV‐2 Spike and Protective Monoclonal Antibodies in COVID‐19 Patients

Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins

A Chimeric Multi-Epitope DNA Vaccine Elicited Specific Antibody Response Against Severe Acute Respiratory Syndrome-Associated Coronavirus Which Attenuated the Virulence of SARS-CoV in Vitro

Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach

A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered Pichia pastoris Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody Responses

Designed peptides as potential fusion inhibitors against SARA-CoV-2 coronavirus infection